ASX RELEASE 13 August 2026 Phase 3 OA Trial Continues Unchanged Following Formal DSMB 80% Safety Review, September Interim Analysis on Track Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or...
80% Safety Review Complete, September IA on Track
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Application for quotation of securities - PAR
- June 2026 Quarterly Activities Report & Appendix 4C
- Paradigm Receives $5.75m R&D Tax Incentive Refund
- Drawdown of Tranche 4 under the Convertible Note Facility
- PAR Completes Enrolment in Pivotal Phase 3
Later from Paradigm Biopharmaceuticals
- Appendix 4G and Corporate Governance Statement
- Appendix 4E and 2026 Annual Report
- Melbourne Investor Lunch
- Notification regarding unquoted securities - PAR
- Notice under Section 708A
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals